|
|
 |
|
Viewing report
|
|
|
|
The Pharmaceutical Market: Switzerland
Espicom Business Intelligence Ltd, Oct 2011, Pages: 54
THE PHARMACEUTICAL MARKET: SWITZERLAND - REVIEW
The Swiss pharmaceutical industry is highly advanced and has long had an international reputation for the quality of its production and research. Two local companies dominate the sector; Novartis and Roche. They are both prominent in the domestic market, although the majority of their sales are earned outside Switzerland. Swiss pharmaceutical exports exceed US$43 billion; the balance of pharmaceutical trade is positive and has demonstrated an upward trend since 2000.
By international standards, the Swiss generic market remains uncompetitive. Over 70% of generic sales are made by two companies; Mepha, acquired by Cephalon in April 2010, and Sandoz. A more competitive environment would almost certainly lead to lower price levels. However, the government’s policy of period price reductions may prove counterproductive in this regard, by making the market less attractive for new players and entrenching the position of the existing manufacturers. A few other companies, notably Teva, Actavis and Sanofi (through Winthrop), are active in the market, but to date have not gained much market share.
There have been several acquisitions by Swiss pharmaceutical companies recently. In April 2011, Novartis completed its merger with Alcon, which is now the new eye care division of Novartis. Previously, in December 2010, Novartis bought the remaining stake in Alcon for US$168 per share, totalling US$12.9 billion. In the biologic sector, Lonza acquired Arch Chemicals for US$1.2 billion in July 2011. In July 2010, Actelion entered a binding agreement to acquire French company Trophos, which specialises in neurodegenerative diseases.
ENHANCED STRATEGIC INTELLIGENCE
These highly regarded world pharmaceutical market reports have been redesigned to provide enhanced strategic intelligence in a user-friendly format. Each report provides in-depth information, setting the pharmaceutical market in context. The reports provide:
- Five-year projections for economic, demographic, health expenditure, health workforce and pharmaceutical market indicators.
- Specialised intelligence on OTCs, generics, biologics and biosimilars.
- Exclusive economic and demographic data from the Economist Intelligence Unit (EIU) for each market in the series.
- A separate statistical health file, comprising health expenditure, health infrastructure, health services and health personnel.
- The reports are updated quarterly, providing you with the latest information for a full year. In addition, the service will keep you up to date with market and industry news on a regular basis.
HEALTHCARE STATISTICS
A comprehensive tabula review, comprising demographics, epidemiology, health expenditure, hospital and primary care infrastructure & services and healthcare personnel, is additionally included.
Customers who bought this item also bought
The Pharmaceutical Market: Canada
The Pharmaceutical Market: Germany
The Pharmaceutical Market: Argentina
The Pharmaceutical Market: Japan
The Pharmaceutical Market: Pakistan
The Pharmaceutical Market: Mexico
The Pharmaceutical Market: China
The Pharmaceutical Market: USA
The Pharmaceutical Market: Malaysia
The Pharmaceutical Market: Australia
|
|
|
|
